AngioDynamics/Rita
This article was originally published in The Gray Sheet
Executive Summary
AngioDynamics subsidiary Rita Medical pays $2,750 to the U.S. government to settle allegations that it traded with an entity in Iran between October 2002 and January 2003 without disclosing the activities to the Treasury Department's Office of Foreign Assets Control, a violation of the Iranian Transactions Regulations. AngioDynamics bought radiofrequency ablation device maker Rita for $220 million in January (1"The Gray Sheet" Dec. 4, 2006, p. 10). Another device maker, EP MedSystems, paid $277,000 to settle similar charges in 2006 and earlier this year
You may also be interested in...
AngioDynamics Will Break Into Oncology Biz With $220 Mil. Rita Purchase
AngioDynamics will gain immediate access to the targeted tumor ablation market and will fill out its vascular access business in a $220 mil. acquisition of Rita Medical
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.